InMed Pharmaceuticals Inc (CSE:IN, OTCQB:IMLFF) provided investors with an update on its biosynthesis program.
According to the company news:
The goal of InMed’s biosynthesis program is to provide an alternate low cost and high quality process for producing phytocannabinoids for its product candidates. Typically, phytocannabinoids are extracted from the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Using metabolic engineering the plant pathway for producing cannabinoids can be recreated in a microbial host and will be devoid of the by-products and impurities seen with extraction. The process can also be performed at industrial-scale allowing for a low cost production of cannabinoids.
Dr. Sazzad Hossain stated:
We have made great progress in the last 8 months developing a comprehensive de novo biosynthesis system for cannabinoids using a multiple metabolic engineering approach and have been able to produce our target cannabinoids on a gram scale basis. Successful production of our target cannabinoids using a biosynthetic process is a significant achievement for InMed and is an important step for our product development program.